PSTV registers amended 2020 Stock Incentive Plan on Form S-8

Rhea-AI Filing Summary

Plus Therapeutics, Inc. submitted a Form S-8 registering employee benefit plans and associated agreements for use with equity awards. The filing lists the Fifth Amended and Restated 2020 Stock Incentive Plan, multiple forms of stock/unit/option agreements, historical employee plans and amendments dating back to 2016 through 2024, and routine legal and accounting opinions and consents. The document is signed by Marc H. Hedrick, M.D. as President and CEO and shows execution by officers and directors on August 22, 2025. The exhibit list and incorporated filings indicate the S-8 is administrative: it registers existing and amended equity-plan documents rather than reporting operating results or new material transactions.

Positive

• Comprehensive exhibit list including plan documents and legal opinions supports clear registration
• Fifth Amended 2020 Stock Incentive Plan is explicitly registered, enabling future equity awards
• Signatures executed by CEO and officers on August 22, 2025, indicating managerial authorization

Negative

• No financial impact disclosed in this filing; it is administrative and does not present operating results
• No effective date for the registration statement is shown in the provided text

Insights

Corporate Securities Counsel

S-8 registers equity plans and supporting legal opinions for employee awards.

The filing enumerates the 2020 Stock Incentive Plan (Fifth Amended), related stock unit and option agreement forms, and earlier employee plans and amendments, with exhibit references to prior 10-K, S-1, S-8, and 8-K filings dated between 2016 and 2024.

Dependencies and risks are procedural: effectiveness depends on the registration statement becoming effective and consistent incorporation by reference to prior filings; there are standard legal opinions and accounting consents included. Monitor administrative milestones such as the effective date of the registration and any subsequent equity grants that would use these plan documents.

As filed with the Securities and Exchange Commission on August 22, 2025

Registration No. 333-   

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

PLUS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		33-0827593
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)
2710 Reed Road, Suite 160 Houston, Texas		77002
(Address of Principal Executive Offices)		(Zip Code)

Fifth Amended and Restated Plus Therapeutics, Inc. 2020 Stock Incentive Plan

Plus Therapeutics, Inc. 2015 New Employee Incentive Plan

(Full title of the Plans)

Marc H. Hedrick, M.D.

President and Chief Executive Officer

Plus Therapeutics, Inc.

2710 Reed Road, Suite 160

Houston, Texas 77002

(737) 255-7194

(Name, address and telephone number of agent for service)

With copies to:

David E. Danovitch

Aaron M. Schleicher

Sullivan & Worcester LLP

1251 Avenue of the Americas

New York, New York 10020

(212) 660-3060

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 under the Exchange Act.

Large accelerated filer		☐		Accelerated filer		☐
Non-accelerated filer		☒		Smaller reporting company		☒
				Emerging growth company		☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

EXPLANATORY NOTE

This Registration Statement (the “Registration Statement”) registers an aggregate of 20,075,000 additional shares of common stock, par value $0.001 per share (the “Common Stock”) of Plus Therapeutics, Inc. (the “Registrant”), consisting of (i) 20,000,000 shares of Common Stock issuable pursuant to the Fifth Amended and Restated Plus Therapeutics, Inc. 2020 Stock Incentive Plan (the “2020 Stock Incentive Plan”), representing an increase of 20,000,000 shares of Common Stock reserved for issuance under the 2020 Stock Incentive Plan, as a result of an amendment thereto, which was adopted by the board of directors (the “Board”) of the Registrant on July 17, 2025 and approved by the Registrant’s stockholders at the Annual Meeting of Stockholders held on August 7, 2025; and (ii) 75,000 shares of Common Stock issuable pursuant to the Plus Therapeutics, Inc. 2015 New Employee Incentive Plan (as amended, the “2015 Plan”), representing an increase of 75,000 shares of Common Stock reserved for issuance under the 2015 Plan, as a result of an amendment thereto, which was adopted by the Board on June 6, 2024. Pursuant to General Instruction E to Form S-8 under the Securities Act of 1933, as amended, the contents of the Registrant’s registration statements on Form S-8 filed with the U.S. Securities and Exchange Commission (the “Commission”) on March 15, 2016 (Registration No. 333-210211), March 9, 2018 (Registration No. 333-223566), June 30, 2020 (Registration No. 333-239548) and on August 23, 2024 (Registration No. 333-281758) are incorporated by reference and made part of this Registration Statement. Any items in such registration statements not expressly changed hereby shall be as set forth in such registration statements.

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3. Incorporation of Documents by Reference.

The following documents filed by Registrant with the Commission are hereby incorporated by reference in this Registration Statement:

(a) the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024 (filed with the Commission on March 31, 2025) and the Amendment to the Registrant’s Annual Report on Form 10-K for the year ended December  31, 2024 (filed with the Commission on April 30, 2025);

(b) all other reports filed by the Registrant pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (the “Exchange Act”) since the end of the fiscal year covered by the document referred to in (a) above (other than the portions of those documents not deemed to be filed); and

(c) the description of the Registrant’s Common Stock contained in Exhibit 4.1 to its Annual Report on Form 10-K for the fiscal year ended December  31, 2024, filed with the Commission on March 31, 2025 (File No. 001-34375).

All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment that indicates that all securities offered hereby have been sold or that deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of the filing of such documents.

Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

Item 8. Exhibits.

Incorporated by Reference

Exhibit Number

Description

Filed Herewith

Form

File Number

Exhibit

Filing Date

5.1

Opinion of Sulivan & Worcester LLP

X

23.1

Opinion of Sullivan & Worcester LLP (included in Exhibit 5.1)

X

23.2

Consent of Independent Registered Public Accounting Firm

X

24.1

Power of Attorney (included on the signature page to this Registration Statement)

X

99.1

Fifth Amended and Restated Plus Therapeutics, Inc. 2020 Stock Incentive Plan

10-Q

001-34375

10.15

08/14/2025

99.2

Form of Stock Unit Agreement under the 2020 Stock Incentive Plan

X

99.3

Form of Notice of Grant and Stock Option Agreement under the 2020 Stock Incentive Plan

10-K

001-34375

10.26

02/24/2022

99.4

2015 New Employee Incentive Plan

8-K

001-34375

10.1

01/05/2016

99.5

First Amendment to the Plus Therapeutics, Inc. 2015 New Employee Incentive Plan, dated January 26, 2017

10-K

001-34375

10.42

03/24/2017

99.6

Second Amendment to the Plus Therapeutics, Inc. 2015 New Employee Incentive Plan, Dated February 6, 2020

10-K

001-34375

10.25

03/30/2020

99.7

Third Amendment to the 2015 New Employee Incentive Plan

S-1

333-280061

10.15

06/07/2024

99.8

Form of Stock Option Agreement under the 2015 New Employee Incentive Plan

S-8

333-210211

99.4

03/15/2016

107

Filing Fee Table

X

SIGNATURES

Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Houston, Texas, on August 22, 2025.

PLUS THERAPEUTICS, INC.
By:		/s/ MARC H. HEDRICK, M.D.
		Name:		Marc H. Hedrick, M.D
		Title:		President and Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Marc H. Hedrick, M.D and Andrew Sims, and each of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and revocation, in his or her name and on his or her behalf, to do any and all acts and things and execute, in the name of the undersigned, any and all instruments which said attorney-in-fact and agent may deem necessary or advisable to enable the Registrant to comply with the Securities Act, and any rules, regulations, or requirements of the Commission in respect thereof, in connection with the filing with the Commission of this Registration Statement under the Securities Act, including specifically but without limitation, power and authority to sign the name of the undersigned to such Registration Statement, and any amendments to such Registration Statement (including post-effective amendments), and to file the same with all exhibits thereto and other documents in connection therewith, with the Commission and any applicable securities exchange or securities regulatory body, to sign any and all applications, registration statements, notices or other documents necessary or advisable to comply with applicable securities laws, including without limitation state securities laws, and to file the same, together with other documents in connection therewith with the appropriate authorities, including without limitation state securities authorities, granting unto said attorney-in-fact and agent, full power and authority to do and to perform each and every act and thing requisite or necessary to be done in and about the premises, as fully and to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute, may lawfully do or cause to be done by virtue hereof. This Power of Attorney may be signed in several counterparts.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities set forth below on August 22, 2025.

Signature		Title		Date
/S/ MARC H. HEDRICK, M.D. MARC H. HEDRICK, M.D.		President, Chief Executive Officer and Director (Principal Executive Officer)		August 22, 2025
/S/ ANDREW SIMS ANDREW SIMS		Chief Financial Officer (Principal Financial and Accounting Officer)		August 22, 2025
/S/ RICHARD J. HAWKINS RICHARD J. HAWKINS		Chair of the Board of Directors		August 22, 2025
/S/ HOWARD CLOWES HOWARD CLOWES		Director		August 22, 2025
/S/ AN VAN ES-JOHANSSON, M.D. AN VAN ES-JOHANSSON, M.D.		Director		August 22, 2025
/S/ ROBERT LENK, PH.D ROBERT LENK, PH.D		Director		August 22, 2025
/S/ KYLE GUSE KYLE GUSE		Director		August 22, 2025

FAQ

What does the S-8 filed by Plus Therapeutics (PSTV) register?

The S-8 registers employee equity plans and related agreement forms, including the Fifth Amended and Restated 2020 Stock Incentive Plan and various stock/unit/option agreement templates.

Does the filing show when the registration becomes effective?

The provided content does not show an effectiveness date for the registration; only execution/signature dates of August 22, 2025 are shown.

Are there legal opinions and accounting consents included with the S-8?

Yes; Exhibit 5.1 contains an opinion of Sullivan & Worcester LLP and Exhibit 23.2 lists the consent of the independent registered public accounting firm.

Which historical plan documents are incorporated by reference?

The exhibit list references prior plan documents and amendments filed on various forms including 10-K, S-1, S-8, and 8-K between 2016 and 2024.

Who signed the registration statement for PSTV?

The document is signed by Marc H. Hedrick, M.D. as President and Chief Executive Officer, with other officers and directors also signing on August 22, 2025.